Compare Novavax Inc (NVAX) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Warner Music Group Corp — how do they compare? Novavax Inc trades at $9.88 (market cap $1.68B), while Warner Music Group Corp trades at $28.16 (market cap $14.66B). The key difference: Warner Music Group Corp is far larger — about 8.7× Novavax Inc's market cap, and Warner Music Group Corp pays a 2.85% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | WMG | |
|---|---|---|
Market Cap | $1.68B | $14.66B |
Sector | Health | Media |
52-Week High | $11.19 | $34.72 |
52-Week Low | $6.22 | $23.65 |
Enterprise Value | $1.26B | $18.96B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
Warner Music Group (WMG) trades at $28.03, down 2.61% on the day, with a bearish technical signal. Recent earnings show mixed quarterly beats, with Q1 and Q2 2026 exceeding expectations but Q4 2025 missing. Revenue has grown steadily from $5.9B in 2022 to $6.7B in 2025, though net income margin declined to 5.44%. The company maintains a strong ROE of 25.38% and recently announced a strategic AI music partnership with Suno (Reuters, 2026-09-09).
Outlook is cautiously optimistic with analyst consensus at 66.7% buy ratings. Key opportunities include streaming growth and AI initiatives, while risks involve margin pressure and leadership changes. The stock's valuation at a P/E of 22.42 appears reasonable given growth prospects, but investors should monitor execution on margin improvement and competitive dynamics in the music industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
